Jeremy Westfall

Background

About Jeremy Westfall

A proven leader with over two decades of medical device, pharmaceutical, and life sciences experience, with over half of those years spent in senior leadership. Award-winning record of success in new-market segmentation and existing market growth in all facets of life science innovation. Client-and team-focused strategic thinker with strong leadership in commercialization and product development. Regulatory and Healthcare economics education with many contributions-Consultant for Kings College, London,"AI for Cancer Research"-Stakeholder for the U.S. House of Representatives, Cures Act 2.1 (2024-Present), U.S. Health and Public Policy Director-Stakeholder for the U.S. House of Representatives, Cures Act 2.0 / ARPA-H (2021-2023), U.S. Health and Public Policy Director-Consultant / Advisor / Speaker for the Critical Path Institute (C-Path). C-PATH is a consortia of over 1,600 scientists from regulatory, academia, patient, and disease foundations which serves as a catalyst for innovation that accelerated the path to a healthier world-Worked with the Senior Executive Director, Office of Research Protection, Policy and Education for the VHA, to help create greater access for Veterans to enroll in clinical trials-Co-Authored rebuttal to FDA pertaining to draft guidance for PRO assessments in oncology clinical trials.*PublishedPapers: “The Trust Deficit: Is An Overlooked Literacy Gap Stalling Clinical Trial Enrollment?” - Clinical Leader, 2025. Clinical Trial Recruitment: Can a Comparative Analysis of Database-Driven, Digital Technology, and Integrated Strategies break the Cycle?” - Clinical Trial Vanguard, 2024.“What Drugs Actually Lead to Additional Years Worth Living" 2021-Developed RPM modeling for commercialization of several emerging technologies-Worked closely with MAC's throughout the U.S. for attainment of TIN reimbursement-Developed and deployed numerous risk sharing models for large medical device companies-Advisor / Consultant for bundled payment modeling and development for private insurance companies, as well as several medical device companies.